Previous studies have suggested that âŁ-glucosidase inhibitors such as castanospermine and deoxynojirimycin inhibit dengue virus type 1 infection by disrupting the folding of the structural proteins prM and E, a step crucial to viral secretion. We extend these studies by evaluating the inhibitory activity of castanospermine against a panel of clinically important flaviviruses including all four serotypes of dengue virus, yellow fever virus, and West Nile virus. Using in vitro assays we demonstrated that infections by all serotypes of dengue virus were inhibited by castanospermine. In contrast, yellow fever virus and West Nile virus were partially and almost completely resistant to the effects of the drug, respectively. Castanospermine inhibited dengue virus infection at the level of secretion and infectivity of viral particles. Importantly, castanospermine prevented mortality in a mouse model of dengue virus infection, with doses of 10, 50, and 250 mg/kg of body weight per day being highly effective at promoting survival (P < 0.0001). Correspondingly, castanospermine had no adverse or protective effect on West Nile virus mortality in an analogous mouse model. Overall, our data suggest that castanospermine has a strong antiviral effect on dengue virus infection and warrants further development as a possible treatment in humans.Dengue fever, the most prevalent arthropod-borne viral illness in humans, is caused by dengue virus (DEN). DEN is a single-stranded, positive-polarity, enveloped RNA virus that is translated in the cytoplasm as a single polyprotein and cleaved into three structural and seven nonstructural proteins. Four related serotypes of DEN exist in nature and are transmitted to humans primarily by two mosquitoes, Aedes aegypti and Aedes albopictus. DEN is a member of the Flaviviridae family and is genetically related to the viruses that cause yellow fever, hepatitis C, and the Japanese, St. Louis, and West Nile encephalitides. DEN infection results in a spectrum of disease ranging from a debilitating, self-limited illness (dengue fever) to a life-threatening syndrome (dengue hemorrhagic fever [DHF]). DEN causes disease globally with an estimated 25 to 100 million new infections per year (34). At present, no vaccine has been approved for human use and treatment is supportive.Flavivirus assembly takes place at the endoplasmic reticulum (ER) (7). The structural glycoproteins prM and E localize to the luminal side of the ER and form an immature particle with prM and E in a heterodimeric complex (7, 58). Furin-mediated proteolysis of prM in the trans-Golgi network (48) triggers rearrangement, homodimerization of E, and formation of the mature viral particle before release from the infected cell (1, 16). In flavivirus-infected mammalian cells, a 14-residue oligosaccharide, (Glc) 3 (Man) 9 (GlcNAc) 2 , is added in the ER to specific asparagine residues on the prM and E proteins. This high-mannose carbohydrate is sequentially modified in the ER by resident âŁ-glucosidases to generate N-linked glycans that lack t...